Now, the trial wasn't designed to isolate which piece of the lifestyle intervention drove the additional loss
A few practical points: if metformin causes lactic acidosis risk (renal impairment, contrast dye exposure, severe illness), it may be held temporarilybut this is independent of semaglutide
Heres a situation every somatotropic researcher eventually runs into: three compounds on the shelf, all of them secretagogues, all hitting GHSR-1a and the protocol decision matters more than most people initially realize
We think about disruption, theres a lot of speculation around this, but some of it definitely has merit, it seems
The best results from treatment with both medications have been observed when they used in conjunction with a healthy diet and regular exercise